Scancell Hldgs Plc (SCLP)

Currency in GBP
9.75
0.00(0.00%)
Closed·
SCLP Scorecard
Full Analysis
Suffers from weak gross profit margins
SCLP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9.509.84
52 wk Range
7.2619.75
Key Statistics
Bid/Ask
9.50 / 11.00
Prev. Close
9.75
Open
9.75
Day's Range
9.5-9.84
52 wk Range
7.26-19.75
Volume
219.32K
Average Volume (3m)
767.71K
1-Year Change
-32.76%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SCLP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
28.50
Upside
+192.31%
Members' Sentiments
Bearish
Bullish
ProTips
Stock price often moves in the opposite direction of the market

Scancell Hldgs Plc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Scancell Hldgs Plc Company Profile

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, melanoma, ovarian, lung, and pancreatic cancers; and Modi-2, which targets homocitrullinated cancer antigens. In addition, the company focuses to develop SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

Compare SCLP to Peers and Sector

Metrics to compare
SCLP
Peers
Sector
Relationship
P/E Ratio
−6.4x−3.1x−0.5x
PEG Ratio
0.23−0.050.00
Price/Book
−6.5x4.0x2.6x
Price / LTM Sales
-13.5x3.2x
Upside (Analyst Target)
192.3%76.9%41.7%
Fair Value Upside
Unlock−1.6%6.1%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 28.50
(+192.31% Upside)

Earnings

Latest Release
Jan 30, 2025
EPS / Forecast
-0.01 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

SCLP Income Statement

FAQ

What Stock Exchange Does Scancell Trade On?

Scancell is listed and trades on the London Stock Exchange stock exchange.

What Is the Stock Symbol for Scancell?

The stock symbol for Scancell is "SCLP."

What Is the Scancell Market Cap?

As of today, Scancell market cap is 101.18M.

What Is Scancell's Earnings Per Share (TTM)?

The Scancell EPS (TTM) is -0.02.

When Is the Next Scancell Earnings Date?

Scancell will release its next earnings report on 23 Oct 2025.

From a Technical Analysis Perspective, Is SCLP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Scancell Stock Split?

Scancell has split 6 times.

How Many Employees Does Scancell Have?

Scancell has 61 employees.

What is the current trading status of Scancell (SCLP)?

As of 26 Jul 2025, Scancell (SCLP) is trading at a price of 9.75, with a previous close of 9.75. The stock has fluctuated within a day range of 9.50 to 9.84, while its 52-week range spans from 7.26 to 19.75.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.